Oklahoma is currently home to 859 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Oklahoma City, Tulsa, Norman and Edmond. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
AltaValve Early Feasibility Study Protocol
NCT03997305
Recruiting
Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open-heart surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Oklahoma Heart Hospital, Oklahoma City, Oklahoma
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence
Register for Updates
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
NCT05076942
Recruiting
Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/27/2023
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
Register for Updates
Exercise-Induced Gut Permeability in Normal-weight Obesity
NCT05889767
Recruiting
Exercise acutely increases gut permeability and inflammation, even in healthy populations. However, whether this response differs in groups at-risk for CVD that present with low-grade inflammation (e.g., normal-weight obesity) has yet to be examined. The investigators aim to measure serum indicators of gut permeability in those with normal-weight obesity pre- and post-short, intense exercise and sustained, moderate exercise
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/02/2023
Locations: 208 Nancy Randolph Davis, Oklahoma State University, Stillwater, Oklahoma
Conditions: Normal-weight Obesity, Obesity
Register for Updates
Physica System Total Knee Replacement Registry Study
NCT03048201
Recruiting
The primary objective of this study is to obtain long-term implant survivorship (out to 10 years) and to assess clinical, patient-reported outcome measures, and radiographic data for the commercially available Physica system. For ancillary arm, from baseline to 5-year follow-up.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/17/2023
Locations: Joint Reconstructive Specialist, Oklahoma City, Oklahoma
Conditions: Osteoarthritis, Knee, Traumatic Arthritis, Avascular Necrosis, Degenerative Joint Disease of Knee, Rheumatoid Arthritis, Deformity of Knee
Register for Updates
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
NCT05007418
Recruiting
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: University of Oklahoma, Oklahoma City, Oklahoma
Conditions: Multiple Myeloma
Register for Updates
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04718818
Recruiting
The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/19/2021
Locations: Research Site, Oklahoma City, Oklahoma
Conditions: Ulcerative Colitis
Register for Updates
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia
NCT04519099
Recruiting
To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 mg/d compared with placebo in prevention of relapse in patients with schizophrenia To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
08/17/2020
Locations: Sooner Clinical Research, Oklahoma City, Oklahoma
Conditions: Schizophrenia
Register for Updates